SEC Company Response from ADIAL PHARMACEUTICALS, INC. (ADIL) (CIK 0001513525) (AZR) — Feb 19, 2019
ADIAL PHARMACEUTICALS, INC. (ADIL) (CIK 0001513525)
Date: Feb. 19, 2019 · CIK: 0001513525 · Accession: 0001213900-19-002775
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-229615
Letter
Re:
February 19, 2019
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
F Street, N.E.
Washington, DC 20549
Attention: Mr. Todd Schiffman
Adial Pharmaceuticals, Inc.
Registration Statement on Form S-1 File No: 333-229615
Ladies and Gentlemen:
As the underwriters of the proposed offering of Adial Pharmaceuticals, Inc. (the “Company”), we hereby join the Company’s request for acceleration of the above-referenced Registration Statement, requesting effectiveness for 5:00 p.m., Eastern Time, on February 20, 2019, or as soon thereafter as is practicable.
Pursuant to Rule 460 of the General Rules and Regulations under the Securities Act of 1933, we wish to advise you that we have effected the following distribution of the Company’s Preliminary Prospectuses dated February 12, 2019 and February 19, 2019 through the date hereof:
Preliminary Prospectuses dated February 12, 2019 and February 19, 2019:
Copies to underwriters:
Copies to prospective dealers:
Copies to prospective institutional investors:
Copies to prospective retail investors:
The undersigned advise that they have complied and will continue to comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very truly yours,
Maxim Group LLC
Show Raw Text
CORRESP
1
filename1.htm
February
19, 2019
VIA
EDGAR
Securities
and Exchange Commission
Division
of Corporation Finance
100
F Street, N.E.
Washington,
DC 20549
Attention:
Mr. Todd Schiffman
Re:
Adial
Pharmaceuticals, Inc.
Registration
Statement on Form S-1 File No: 333-229615
Ladies
and Gentlemen:
As
the underwriters of the proposed offering of Adial Pharmaceuticals, Inc. (the “Company”), we hereby
join the Company’s request for acceleration of the above-referenced Registration Statement, requesting effectiveness for
5:00 p.m., Eastern Time, on February 20, 2019, or as soon thereafter as is practicable.
Pursuant
to Rule 460 of the General Rules and Regulations under the Securities Act of 1933, we wish to advise you that we have effected
the following distribution of the Company’s Preliminary Prospectuses dated February 12, 2019 and February 19, 2019 through
the date hereof:
Preliminary
Prospectuses dated February 12, 2019 and February 19, 2019:
Copies to underwriters:
2
Copies to prospective dealers:
12
Copies to prospective institutional investors:
225
Copies to prospective retail investors:
430
The
undersigned advise that they have complied and will continue to comply with Rule 15c2-8 under the Securities Exchange Act of 1934,
as amended.
Very truly yours,
Maxim Group LLC
By:
/s/
Clifford A. Teller
Name:
Clifford A. Teller
Title: Head
of Investment Banking,
Executive Managing Director
Joseph Gunnar & Co., LLC
By:
/s/
Stephan Stein
Name:
Stephan Stein
Title: President